Insights Into Nicotinic Receptor Signaling in Nicotine Addiction: Implications for Prevention and Treatment

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2017 Aug 2

PMID 28762314

Citations 12

Authors

Wuyi Liu

Ming D Li

Affiliations

Soon will be listed here.

Abstract

Background: Nicotinic acetylcholine receptors (nAChRs) belong to the Cys-loop ligandgated ion-channel (LGIC) superfamily, which also includes the GABA, glycine, and serotonin receptors. Many nAChR subunits have been identified and shown to be involved in signal transduction on binding to them of either the neurotransmitter acetylcholine or exogenous ligands such as nicotine. The nAChRs are pentameric assemblies of homologous subunits surrounding a central pore that gates cation flux, and they are expressed at neuromuscular junctions throughout the nervous system.

Methods And Results: Because different nAChR subunits assemble into a variety of pharmacologically distinct receptor subtypes, and different nAChRs are implicated in various physiological functions and pathophysiological conditions, nAChRs represent potential molecular targets for drug addiction and medical therapeutic research. This review intends to provide insights into recent advances in nAChR signaling, considering the subtypes and subunits of nAChRs and their roles in nicotinic cholinergic systems, including structure, diversity, functional allosteric modulation, targeted knockout mutations, and rare variations of specific subunits, and the potency and functional effects of mutations by focusing on their effects on nicotine addiction (NA) and smoking cessation (SC). Furthermore, we review the possible mechanisms of action of nAChRs in NA and SC based on our current knowledge.

Conclusion: Understanding these cellular and molecular mechanisms will lead to better translational and therapeutic operations and outcomes for the prevention and treatment of NA and other drug addictions, as well as chronic diseases, such as Alzheimer's and Parkinson's. Finally, we put forward some suggestions and recommendations for therapy and treatment of NA and other chronic diseases.

Citing Articles

Cholinergic Mechanisms in Gastrointestinal Neoplasia.

Sampaio Moura N, Schledwitz A, Alizadeh M, Kodan A, Njei L, Raufman J Int J Mol Sci. 2024; 25(10).

PMID: 38791353 PMC: 11120676. DOI: 10.3390/ijms25105316.

Expression of Chrna9 is regulated by Tbx3 in undifferentiated pluripotent stem cells.

Yazawa T, Imamichi Y, Kitano T, Islam M, Khan M, Takahashi S Sci Rep. 2023; 13(1):1611.

PMID: 36709241 PMC: 9884305. DOI: 10.1038/s41598-023-28814-7.

Smoking-mediated nicotinic acetylcholine receptors (nAChRs) for predicting outcomes for head and neck squamous cell carcinomas.

Shen Y, Huang Q, Ji M, Hsueh C, Zhou L BMC Cancer. 2022; 22(1):1093.

PMID: 36284268 PMC: 9594873. DOI: 10.1186/s12885-022-10161-x.

Interactions between cigarette smoking and cognitive status on functional connectivity of the cortico-striatal circuits in individuals without dementia: A resting-state functional MRI study.

Qiu T, Xie F, Zeng Q, Shen Z, Du G, Xu X CNS Neurosci Ther. 2022; 28(8):1195-1204.

PMID: 35506354 PMC: 9253779. DOI: 10.1111/cns.13852.

Smoking and the Pathophysiology of Peripheral Artery Disease.

Wang W, Zhao T, Geng K, Yuan G, Chen Y, Xu Y Front Cardiovasc Med. 2021; 8:704106.

PMID: 34513948 PMC: 8429807. DOI: 10.3389/fcvm.2021.704106.

References

Young G, Zwart R, Walker A, Sher E, Millar N . Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A. 2008; 105(38):14686-91. PMC: 2535569. DOI: 10.1073/pnas.0804372105. View

Zhao-Shea R, Liu L, Pang X, Gardner P, Tapper A . Activation of GABAergic neurons in the interpeduncular nucleus triggers physical nicotine withdrawal symptoms. Curr Biol. 2013; 23(23):2327-35. PMC: 3855889. DOI: 10.1016/j.cub.2013.09.041. View

Booker T, Butt C, Wehner J, Heinemann S, Collins A . Decreased anxiety-like behavior in beta3 nicotinic receptor subunit knockout mice. Pharmacol Biochem Behav. 2007; 87(1):146-57. DOI: 10.1016/j.pbb.2007.04.011. View

Brunzell D, McIntosh J, Papke R . Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation. Ann N Y Acad Sci. 2014; 1327:27-45. PMC: 4197117. DOI: 10.1111/nyas.12421. View

Salas R, Sturm R, Boulter J, De Biasi M . Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J Neurosci. 2009; 29(10):3014-8. PMC: 3862238. DOI: 10.1523/JNEUROSCI.4934-08.2009. View

Guerrini G, Ciciani G . Benzodiazepine receptor ligands: a patent review (2006-2012). Expert Opin Ther Pat. 2013; 23(7):843-66. DOI: 10.1517/13543776.2013.782005. View

Benwell M, Balfour D, Anderson J . Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem. 1988; 50(4):1243-7. DOI: 10.1111/j.1471-4159.1988.tb10600.x. View

Grady S, Moretti M, Zoli M, Marks M, Zanardi A, Pucci L . Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release. J Neurosci. 2009; 29(7):2272-82. PMC: 2680386. DOI: 10.1523/JNEUROSCI.5121-08.2009. View

Luetje C, Patrick J . Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci. 1991; 11(3):837-45. PMC: 6575344. View

10.

Brown R, Collins A, Lindstrom J, Whiteaker P . Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. J Neurochem. 2007; 103(1):204-15. DOI: 10.1111/j.1471-4159.2007.04700.x. View

11.

Zhang Q, Du Y, Zhang J, Xu X, Xue F, Guo C . Functional Impact of 14 Single Nucleotide Polymorphisms Causing Missense Mutations of Human α7 Nicotinic Receptor. PLoS One. 2015; 10(9):e0137588. PMC: 4560414. DOI: 10.1371/journal.pone.0137588. View

12.

Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I . Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol. 2009; 78(7):703-11. DOI: 10.1016/j.bcp.2009.05.024. View

13.

Zhao-Shea R, Liu L, Soll L, Improgo M, Meyers E, McIntosh J . Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology. 2011; 36(5):1021-32. PMC: 3077271. DOI: 10.1038/npp.2010.240. View

14.

Li P, McCollum M, Bracamontes J, Steinbach J, Akk G . Functional characterization of the α5(Asn398) variant associated with risk for nicotine dependence in the α3β4α5 nicotinic receptor. Mol Pharmacol. 2011; 80(5):818-27. PMC: 3198915. DOI: 10.1124/mol.111.073841. View

15.

Balfour D . The role of mesoaccumbens dopamine in nicotine dependence. Curr Top Behav Neurosci. 2015; 24:55-98. DOI: 10.1007/978-3-319-13482-6_3. View

16.

Gotti C, Clementi F . Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2005; 74(6):363-96. DOI: 10.1016/j.pneurobio.2004.09.006. View

17.

Tammimaki A, Herder P, Li P, Esch C, Laughlin J, Akk G . Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by α3β4α5 nicotinic acetylcholine receptors. Neuropharmacology. 2012; 63(6):1002-11. PMC: 3661904. DOI: 10.1016/j.neuropharm.2012.07.022. View

18.

Grady S, Salminen O, Laverty D, Whiteaker P, McIntosh J, Collins A . The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol. 2007; 74(8):1235-46. PMC: 2735219. DOI: 10.1016/j.bcp.2007.07.032. View

19.

Gronlien J, Hakerud M, Ween H, Thorin-Hagene K, Briggs C, Gopalakrishnan M . Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol. 2007; 72(3):715-24. DOI: 10.1124/mol.107.035410. View

20.

Cornuz J . Smoking cessation interventions in clinical practice. Eur J Vasc Endovasc Surg. 2007; 34(4):397-404. DOI: 10.1016/j.ejvs.2007.06.009. View